BRAF and colorectal carcinoma: Accordingly, we show that CCT3833 is active against a panel of KRAS-mutant PDAC, CRC and NSCLC cell lines, whereas it is less potent against KRAS/BRAF wild-type cells (Figure 2A, Supplementary Table S1, available at https://doi.org/10.1016/j.annonc.2020.10.483).